Full text is available at the source.
Expanding and understanding the CRISPR toolbox for Bacillus subtilis with MAD7 and dMAD7
Using MAD7 and dMAD7 to improve gene editing tools for Bacillus subtilis
AI simplified
Abstract
Editing rates of 93% and 100% were established using the MAD7 nuclease for gene editing in Bacillus subtilis.
- MAD7 is a newly available CRISPR nuclease that can be used without licensing fees for industrial research and development.
- The first catalytically inactive variant of MAD7 (dMAD7) was engineered, demonstrating its potential for gene regulation.
- dMAD7 achieved up to 71.3% reduction in gene expression at single and multiple target sites in B. subtilis.
- The research confirmed that the DNA double-strand breaks induced by the nuclease facilitate selection during gene editing.
AI simplified